You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
OKYO Pharma Ltd will participate in the 2026 Jefferies Global Healthcare Conference in London, United Kingdom, taking place November 16–19, 2026, with its leadership team available for one-on-one investor meetings.
OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain, with patients receiving 4 drops per day for 12 weeks across sites in the United States and Europe.
OKYO Pharma announced it will present at Eyecelerator and participate at the American Academy of Optometry and American Academy of Ophthalmology. It plans a global Phase 3 pivotal trial of single-dose urcosimod for neuropathic corneal pain, enrolling approximately 111 patients.
